Tailor-made molecules for your applications
(0 item) - CHF0.00

You have no items in your shopping cart.

ABOUT SPIROCHEM

aboutus

 

SpiroChem AG: Tailor-made molecules to design the drugs of tomorrow.

SpiroChem AG is a Swiss fine chemicals company, based in Zürich, Switzerland. We are specialized in the design, synthesis, production and commercialization of novel building blocks for use in drug discovery.

With cutting-edge know-how in drug design and proprietary process chemistry technologies, SpiroChem is the ideal collaboration partner for large, medium and small pharmaceutical, agrochemical and life science companies. Our clients are located worldwide, including 16 of the top 20 pharma companies.

Our unique repertoire of molecular fragments was designed to help medicinal chemists accelerate drug discovery and lead optimization programs in the Life Science sector. In particular, our products and associated services allow scientists and medicinal chemists to improve ADME properties and design better drugs for tomorrow. SpiroChem is now recognized as the world-leading company on the concept of bioisosterism. In particular, we have established a leadership position on the highly sought-after field of conformationally-restricted molecules and the concept of bioisosterism. We can offer bioisosteric replacements for a variety of functional groups, such as acids, amides, heterocycles, lipophilic groups and benzenes. In particular, we have developed scalable processes to bicyclo[1.1.1]pentane scaffolds and we can also provide many oxetanes, spirocycles and cubanes on scale. If you are looking for expertise in bicyclo[1.1.1]pentane or any of these chemical series, you are at the right place! We have very competitive prices and our technology allows the largest diversity, scalability and the shortest lead times!

SpiroChem services range from catalog products to custom synthesis, FTE/FFS contracts and consultancy. Beyond the supply of a portfolio of innovative catalog products, our personalized services to our clients include:

1) supporting lead optimization programs to quickly improve ADME properties of drug candidates

2) entering into new chemical space and expand their IP-portfolio and strengthen their IP position

SpiroChem AG is registered and has research laboratories in Zurich, Switzerland. We are committed to high quality and success. Challenging chemistry is not an issue for us and we are here to support our clients on the way to success.

We have ongoing collaborations with key academic groups and technology companies worldwide. To accelerate penetration of our products on the market, we have also established a strong network of distributors worldwide, so that our clients can buy directly from us or from their usual chemicals suppliers.

SpiroChem AG and the SpiroTeam are the laureates of several competitions and recipient of awards, including the IMD-Start-up award, Venture Leaders China and the EFMC prize for Young Medicinal Chemist in Industry. SpiroChem is also the recipient of two CTI grants.

SpiroChem - Tailor-made molecules

 

Thomas

Thomas Fessard, PhD - CEO

Thomas studied chemistry in France (ENSC, Montpellier) and the UK (UMIST, Manchester) and obtained a PhD degree from the university of Nottingham, UK.

After research appointments at the School of Pharmacy in Nottingham and ETH Zürich, Thomas joined Lipideon Biotechnology AG in 2007. As Head of the Drug Discovery and Chemistry, he lead a multi-disciplinary team that discovered a candidate for pre-clinical investigation (Non-Systemic Cholesterol Absorption Inhibitor).

In 2011, Thomas co-founded SpiroChem AG and serves as CEO of the company.

Thomas has several years of experience in the management of R&D projects, including medicinal chemistry, design of innovative building blocks for drug discovery and development of new process routes.

 

Nolwenn Daubin - Business Development & Marketing Manager

Nolwenn graduated from the Business School ENACOM and the Chamber of Commerce and Industry of Nantes with a specialization in International Trade.

After several years working as a business developer at a French CRO specialized in organic chemistry and custom synthesis, she joined the SpiroChem team to support business and marketing development.

She is your contact for all inquiries.

 

Florent

Florent Beaufils, PhD – COO

Florent has over 10 years of accomplishments in the Pharma/Biotech industry. His professional experience includes the discovery, process and preclinical development of various protein kinase inhibitors for the treatment of cancer (PQR309, FDA Orphan Drug Designation in 2016) and CNS disorders (PQR620), and a successful technology transfer (2009) with New England Biolabs (SNAP-tag®, CLIP-tag™).

Florent received his Ph.D. in Organic Chemistry at the University of Bern in 2004, and carried out postdoctoral work on total synthesis with Alois Fürstner at the Max Planck Institute für Kohlenforschung in 2005. He was Head of Chemistry and Quality Control at Covalys Biosciences AG (Switzerland) (2005 - 2009), Senior Researcher at the Department of Biomedicine of the University of Basel (2009 - 2012) and Deputy Head of Chemistry at PIQUR Therapeutics AG (2012 - 2016).

Florent is co-author of numerous high impact scientific publications and co-inventor of 10 patents in the areas of drug discovery, process development and biological research.

Peter

Peter Harboe-Schmidt, MSc, MBA (IMD) (Chairman)

Peter brings a wealth of start-up and industry experience from small and large biotech companies. He was co-founder and acting CEO of Xigen Pharma and was previously head of Business Development at Modex Therapeutics, playing a key role for its IPO on the Swiss Stock exchange. Prior to this, he was Head of Market Research and Business Planning with Amgen Europe where he led a pan-European market research organization. Before that he worked in various managerial positions with DuPont de Nemours in manufacturing, sales and Business Development. As a CTI Startup coach, he has coached the founders and CEOs of over 30 Swiss life science companies.

 

Erick

Prof. Erick M. Carreira, PhD

Erick obtained a B.S. degree from the University of Illinois at Urbana­Champaign and a Ph.D. degree from Harvard University. After carrying out postdoctoral work with Peter Dervan at the California Institute of Technology through late 1992, he joined the faculty at the same institution and was promoted to the rank of full professor. Since 1998, he has been full professor of Organic Chemistry at the ETH Zürich. He is the recipient of many academic and industrial awards. His research program focuses on the asymmetric synthesis of biologically active, stereochemically complex, natural products.

Recent advances from the Carreira group in the design of novel building blocks for drug discovery have had a high impact in the pharmaceutical industry and are the basis of the foundation of SpiroChem AG.

 

Thomas

Thomas Fessard, PhD

Thomas studied chemistry in France (ENSC, Montpellier) and the UK (UMIST, Manchester) and obtained a PhD degree from the university of Nottingham, UK.

After research appointments at the School of Pharmacy in Nottingham and ETH Zürich, Thomas joined Lipideon Biotechnology AG in 2007. As Head of the Drug Discovery and Chemistry, he lead a multi-disciplinary team that discovered a candidate for pre-clinical investigation (Non-Systemic Cholesterol Absorption Inhibitor).

In 2011, Thomas co-founded SpiroChem AG and serves as CEO of the company.

Thomas has several years of experience in the management of R&D projects, including medicinal chemistry, design of innovative building blocks for drug discovery and development of new process routes.

 

Anthony

Dr. Anthony D. Baxter, PhD

Dr. Anthony Baxter is a serial entrepreneur and past CEO of several successful science-based CROs: Cyprotex plc, sold (2016) to Evotec (58 mio £) | Argenta Discovery, sold (2014) to CRL (30 mio £).

He has held C-level and Chairman posts at Oxford Asymmetry Ltd, sold (2000) to Evotec (360 mio £), deltaDOT Ltd, Glythera Ltd, DNAmeIT Ltd amongst others.

Before becoming an entrepreneur, Tony worked as a medicinal chemist with 13 years senior level experience with GSK (1983-1990) and Ciba-Geigy UK (now Novartis, 1990-1995).

Tony graduated from the University of Manchester in Salford, UK (MSc, PhD)